SAN DIEGO--(BUSINESS WIRE)--Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products, announced that on March 12, 2009 the company received a Staff Determination letter from NASDAQ (the “Delisting Notice”) indicating that the Company is subject to delisting proceedings due to non-payment of certain outstanding fees as required for continuing listing set forth in NASDAQ’s Marketplace Rule 4310(c)(13). If the Company elects not to appeal the Delisting Notice, the trading of the Company’s common stock will be suspended at the opening of business on March 23, 2009, and a Form25-NSE will be filed with the SEC which will remove the Company’s common stock from listing and registration on The NASDAQ Stock Market. The Company currently does not plan to file an appeal for the Delisting Notice. Nanogen has filed a Form 8-K with the SEC with additional details about the company’s listing status.
